Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Intra-Cellular Therapies
Pharma
J&J touts Caplyta win in 1 of 2 bipolar manic episode studies
Caplyta helped deliver rapid improvement in manic symptoms and overall illness severity versus placebo in adults with bipolar-related manic episodes.
Fraiser Kansteiner
Sep 21, 2026 2:30pm
FDA signs off on depression label expansion for J&J's Caplyta
Nov 6, 2025 8:43am
How J&J CEO broke a stalemate and won Intra-Cellular in M&A push
Feb 7, 2025 11:24am
J&J acquires CNS specialist Intra-Cellular for $14.6B
Jan 13, 2025 10:29am
Intra-Cellular's unstoppable Caplyta nails another trial
Nov 5, 2024 10:15am
Intra-Cellular closing in on major depression nod for Caplyta
Jun 18, 2024 11:40am
